Last reviewed · How we verify

Placebo enteric-coated tablet

POLYSAN Scientific & Technological Pharmaceutical Company · Phase 3 active Small molecule Under review

Placebo enteric-coated tablet is a Small molecule drug developed by POLYSAN Scientific & Technological Pharmaceutical Company. It is currently in Phase 3 development for Treatment of symptoms associated with irritable bowel syndrome. Also known as: povidone, calcium stearate, hypromellose, polysorban, dyes.

Placebo enteric-coated tablets are used in clinical trials to study various conditions, including osteoarthritis of the thumb, epilepsy, and coronary heart disease. The enteric coating is derived from the husks of the Indian plantain seed, also known as ispaghula husks.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePlacebo enteric-coated tablet
Also known aspovidone, calcium stearate, hypromellose, polysorban, dyes
SponsorPOLYSAN Scientific & Technological Pharmaceutical Company
ModalitySmall molecule
PhasePhase 3

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo enteric-coated tablet

What is Placebo enteric-coated tablet?

Placebo enteric-coated tablet is a Small molecule drug developed by POLYSAN Scientific & Technological Pharmaceutical Company, indicated for Treatment of symptoms associated with irritable bowel syndrome.

What is Placebo enteric-coated tablet used for?

Placebo enteric-coated tablet is indicated for Treatment of symptoms associated with irritable bowel syndrome.

Who makes Placebo enteric-coated tablet?

Placebo enteric-coated tablet is developed by POLYSAN Scientific & Technological Pharmaceutical Company (see full POLYSAN Scientific & Technological Pharmaceutical Company pipeline at /company/polysan-scientific-technological-pharmaceutical-company).

Is Placebo enteric-coated tablet also known as anything else?

Placebo enteric-coated tablet is also known as povidone, calcium stearate, hypromellose, polysorban, dyes.

What development phase is Placebo enteric-coated tablet in?

Placebo enteric-coated tablet is in Phase 3.

What are the side effects of Placebo enteric-coated tablet?

Common side effects of Placebo enteric-coated tablet include Nausea, Abdominal pain.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing